Pasithea Therapeutics (KTTA), Aditxt (ADTX), and HeartBeam (BEAT) are the 3 Penny Stocks to watch on December 2, 2025, based on TipRanks’ Penny Stock Screener tool. Penny stocks are shares usually priced at $5 or below and represent companies with a market value under $300 million.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The Penny Stock Screener allows investors to identify stocks by applying a variety of filters, including Sector, Price Target Upside, Smart Score, Analyst Consensus, Dollar Volume, and Price Change.
We leveraged the tool to identify the top three penny stocks with the highest Dollar Volume as of market close on December 1, 2025. Dollar Volume refers to the total value of shares traded in a day, calculated by multiplying the number of shares traded by the stock’s price.
Pasithea Therapeutics – Pasithea Therapeutics is a clinical-stage biotechnology firm, focused on innovative therapies for central nervous system (CNS) disorders and RASopathies. On December 1, KTTA had a Dollar Volume of $244.41 million, while its stock price fell by nearly 21%.
Pasithea Therapeutics secured a $1 million ALS Association grant for a Phase 1 trial of PAS-004 in 12 ALS patients. The study evaluates safety, tolerability, and early efficacy via ALSFRS-R scores and neurofilament levels over 28 weeks.
Aditxt – Aditxt develops biotech technologies to map, monitor, and reprogram the immune system for better health in immune disorders, allergies, and transplants. On Monday, ADTX had a Dollar Volume of $94.84 million, while its stock price dropped by 26%.
There is no specific reason that justifies Aditxt’s stock price decline. However, shares have been volatile lately, losing nearly 57% over the past month.
HeartBeam – HeartBeam is a MedTech company that developed the HeartBeam AIMIGo, a portable, credit card-sized, cable-free ECG device. Yesterday, BEAM had a Dollar Volume of $77.04 million, while its stock price fell 6.5%.
HeartBeam announced its regulatory strategy after receiving a “Not Substantially Equivalent” (NSE) decision from the FDA on its 510(k) submission for 12-lead ECG Synthesis Software, which converts 3D ECG signals from its cable-free device into a full 12-lead ECG. The company, citing its successful VALID-ECG study, plans parallel paths like a 60-day formal appeal or 510(k) resubmission, with FDA discussions indicating labeling changes could resolve issues.
To find more penny stocks like these, you can take a look at TipRanks’ Penny Stock Screener tool. It shows a list of all penny stocks, their price movement, and other vital data.